Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-10-31 | $94,480,000 | reported | |
| FY 2024 | 2024-10-31 | $38,315,000 | reported | |
| FY 2023 | 2023-10-31 | $16,458,000 | reported | |
| FY 2022 | 2022-10-31 | $15,467,000 | reported |
enGene Therapeutics Inc. · CIK 1980845 · Engraved from SEC EDGAR
FY2025 figures · derived
enGene Therapeutics Inc. is the 98th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
Latest filing Nov 16, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2023 | $0.00 | — | $0.00 | $0.00 | 23.20M sh | +3,384.4% | — |
67 managers · Quarter ended Sep 30, 2026All holders ›
141 transaction
Corporate Presentation Non-Viral Genetic Medicine